Your Search for Abacavir or Ziagen matched 1000 Documents (Page 1 of 34).
You may want to refine your search. Results Indexed by relevance.
Abstract: Diagnosis of hypersensitivity reaction to abacavir occurred in 2 to 3% of subjects not receiving abacavir in double-blinded studies. Most cases had rash alone or rash accompanied by non-specific, mild symptoms. These data underscore the importance of assessing hypersensitivity reactions to abacavir as a multi-symptom s ...
http://www.aegis.org/conferences/lipo/2003/134.html
File Name: 134.html, Size: 6KB, Last Modified: Wednesday, July 09, 2003 at 6:29:23 AM
Abstract: Concomitant use of zidovudine in abacavir combination regimen was associated with the absence of K65R and a significantly lower incidence of L74V than regimens without zidovudine. These results suggest that zidovudine may be useful in delaying resistance to abacavir and tenofovir, two drugs which select for the K65R. ...
http://www.aegis.org/conferences/hivdrw/2002/129.html
File Name: 129.html, Size: 7KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: Phenotypic resistance to abacavir correlated with resistance to other NRTIs in our cohort where all patients were >3NRTI-experienced. In this cohort the use of abacavir per se does not seem to be associated with better virological or immunological outcome. ...
http://www.aegis.org/conferences/hivdrts/2001/128.html
File Name: 128.html, Size: 7KB, Last Modified: Monday, June 04, 2001 at 8:12:04 PM
Abstract: Abacavir (1592U89) is a nucleoside reverse transcriptase inhibitor with potent activity against human immunodeficiency virus type 1 (HIV-1) when used alone or in combination with other antiretroviral agents. The present study was conducted to determin ...
http://www.aegis.org/aidsline/2000/dec/a00c0518.html
File Name: a00c0518.html, Size: 11KB, Last Modified: Thursday, December 28, 2000 at 8:12:04 PM
Abstract: De plus en plus de traitements font l'objet d'essais sous forme de formulations uniquotidiennes (une prise par jour). Rien d'étonnant alors à ce que l'on envisage une telle posologie simple pour l'abacavir (ABC). ...
http://www.aegis.org/pubs/catie/2003/catf13804.html
File Name: catf13804.html, Size: 10KB, Last Modified: Tuesday, March 06, 2007 at 6:44:51 PM
Abstract: Our findings highlight that predictive values of HLA-B region typing vary among different populations, even within the Caucasoid subgroups. Thus, if a positive result for the hypersensitive aplotype HLA-B57, DR7 and DQ3 may allow clinicians to reduce the risk of hypersensitivity reaction withholding abacavir from such ...
http://www.aegis.org/conferences/eacs/2003/280.html
File Name: 280.html, Size: 6KB, Last Modified: Saturday, October 25, 2003 at 12:00:00 PM
Abstract: Mutational patterns differed depending on the drug combination examined. Interestingly, with wild-type virus both abacavir/tenofovir and lamivudine/tenofovir <i>in vitro</i> selected for the K65R mutation. With NRTI-resistant variants, the M184V was deselected with tenofovir alone but this was prevented by the addition ...
http://www.aegis.org/conferences/hivdrw/2002/44.html
File Name: 44.html, Size: 7KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: BACKGROUND: The use of abacavir , a potent HIV nucleoside analogue reverse transcriptase inhibitor, is complicated by a potentially life-threatening hypersensitivity syndrome in approximately 5% of cases. Genetic factors influencing the immune response to abacavir may confer susceptibility. METHODS: Major histocomp ...
http://www.aegis.org/conferences/croi/2002/91.html
File Name: 91.html, Size: 7KB, Last Modified: Sunday, February 24, 2002 at 8:12:04 PM
Abstract: Presence of HLA-B*5701 is highly predictive of abacavir HSR in the Western Australian HIV Cohort, with evidence that an abacavir-specific Class I-restricted immune response may involve the concurrence of HLA-B*5701 and a second locus within the central MHC that is carried on the 57.1 extended haplotype. ...
http://www.aegis.org/conferences/lipo/2003/21.html
File Name: 21.html, Size: 7KB, Last Modified: Wednesday, July 09, 2003 at 6:29:23 AM
Abstract: The interpretation of genotypic resistance to didanosine and abacavir is extremely heterogeneous among tested IS. Abacavir scores from a single IS and didanosine scores from three of 11 analysed IS correctly discriminate virological outcomes of salvage regimens containing these agents. ...
http://www.aegis.org/conferences/hivdrw/2002/92.html
File Name: 92.html, Size: 6KB, Last Modified: Wednesday, July 03, 2002 at 6:29:23 AM
Abstract: LONDON -- United Kingdom pharmaceutical group Glaxo Wellcome PLC said Friday that it has received approval from the European Commission to market its anti-HIV medicine Ziagen in all 15 countries of the European Union. Ziagen is indicated in combination therapy for the trea ...
http://www.aegis.org/news/wsj/1999/wj990701.html
File Name: wj990701.html, Size: 10KB, Last Modified: Friday, July 09, 1999 at 3:00:00 PM
Abstract: On July 18, 2008, FDA approved changes to the package insert for Ziagen (abacavir sulfate) highlighting information about the association of the HLA-B*5701 allele (a part of a gene) and hypersensitivity reactions (HSR) caused by abacavir-containing therapy. ...
http://www.aegis.org/news/fda/2008/fd080701.html
File Name: fd080701.html, Size: 16KB, Last Modified: Thursday, November 06, 2008 at 5:24:12 PM
Abstract: On 19 December 2008, FDA approved abacavir (Ziagen) 300 mg scored tablets with corresponding dosing information for paediatric patients weighing 14 kg or more using the scored tablet. ...
http://www.aegis.org/pubs/i-base/2009/ib2009-01-22.html
File Name: ib2009-01-22.html, Size: 7KB, Last Modified: Tuesday, November 10, 2009 at 8:12:04 PM
Abstract: No significant change in biomarker profile known to be related to cardiovascular risk was detected in association with abacavir use. In fact, all significant changes from baseline appeared beneficial, possibly attributable to either anti-HIV effects or cessation of thymidines. ...
http://www.aegis.org/conferences/lipo/2008/p-40.html
File Name: p-40.html, Size: 7KB, Last Modified: Thursday, November 06, 2008 at 7:12:04 PM
Abstract: Catie, AEGiS, HIV, AIDS, Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, Abacavir, hypersensitivity syndrome, HS, abacavir allergies, side effects, HAART. ANTI-HIV AGENTS: Who gets abacavir allergies? TreatmentUpdate 138 - 2003 October; Volume 15 Issue 6 Hosein SRAlthough it is a useful p ...
http://www.aegis.org/pubs/catie/2003/cate13805.html
File Name: cate13805.html, Size: 8KB, Last Modified: Tuesday, March 06, 2007 at 6:44:50 PM
Abstract: The sensitivity of HLAB*5701 in the Thai sample set is comparable to that previously observed by GSK in Caucasians. These results should be viewed as preliminary; independent confirmation of this association would be valuable. As HLAB*5701 is not fully predictive and because of a risk of more serious abacavir HSR upo ...
http://www.aegis.org/conferences/lipo/2005/103.html
File Name: 103.html, Size: 6KB, Last Modified: Monday, November 14, 2005 at 6:29:23 AM
Abstract: GlaxoWellcome Inc. has just released a revised product warning for its drug, abacavir sulfate (Ziagen). This nucleoside analogue reverse transcriptase inhibitor is used with other antiretrovirals for the treatment of HIV-1 infection. ...
http://www.aegis.org/pubs/rita/1999/abacwarn.html
File Name: abacwarn.html, Size: 6KB, Last Modified: Monday, February 02, 2004 at 11:16:20 PM
Abstract: M184V alone does not confer resistance to abacavir. However, resistance rises to a level which may be clinically relevant if zidovudine mutations are additionally present. Thus, abacavir resistance combines the resistance profiles of thymidine and cytosine analogues. This may indicate that cross-resistance is also freq ...
http://www.aegis.org/conferences/hivdrts/2001/70.html
File Name: 70.html, Size: 6KB, Last Modified: Monday, June 04, 2001 at 8:12:04 PM
Abstract: <p><b>OBJECTIVE:</b> Evaluation of clinical resistance to abacavir in various patient populations and correlation with in vitro phenotypic and genotypic assessments.</p> <p><b>METHODS:</b> Plasma samples from naïve and treatment experienced HIV-1 infected patients (adult and pediatric) were assessed for baseline pheno ...
http://www.aegis.org/conferences/croi/1998/686.html
File Name: 686.html, Size: 6KB, Last Modified: Sunday, February 01, 1998 at 8:12:04 PM
Abstract: AEGiS, Rio de Janeiro, 3rd IAS Conference on HIV Pathogenesis and Treatment, TuPe2.3C20, Cardiovascular risk and other toxicities, International AIDS Society, IAS, HIV, AIDS. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005CHRONIC IN VITRO ABACAVIR ...
http://www.aegis.org/conferences/iashivpt/2005/tupe2-3c20.html
File Name: tupe2-3c20.html, Size: 9KB, Last Modified: Monday, July 25, 2005 at 6:29:23 AM
Abstract: AEGIS, 8th EUROPEAN CONFERENCE ON CLINIC ASPECTS AND TREATMENT OF HIV - INFECTION. Abstract Form. REFERENCE NUMBER : 140. ECCATH ID : P82. 8th EUROPEAN CONFERENCE ON CLINIC ASPECTS AND TREATMENT OF HIV - INFECTION. Location of research or project (country). SPAIN. Thematic Areas:. 5. ...
http://www.aegis.org/conferences/eacs/2001/posters/237.html
File Name: 237.html, Size: 7KB, Last Modified: Monday, December 29, 2003 at 10:30:24 PM
Abstract: <p><b>BACKGROUND:</b> Hypersensitivity reactions are important early toxicities which lead to drug discontinuation and limit the choices of therapy. The reported incidence is 7-17% with nevirapine and 3-13% with abacavir . The risk factors for the development of hypersensitivi ...
http://www.aegis.org/conferences/iac/2002/b10365.html
File Name: b10365.html, Size: 8KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
Abstract: Switching from a PI to abacavir gives a trend of improved cholesterol and insulin tolerance test at 48 weeks. These study results should be confirmed in larger comparative trials. ...
http://www.aegis.org/conferences/lipo/2000/p89.html
File Name: p89.html, Size: 6KB, Last Modified: Thursday, September 14, 2000 at 6:29:23 AM
Abstract: Abacavir (1592U89) is a nucleoside inhibitor of human immunodeficiency virus (HIV) type 1 reverse transcriptase (RT). Resistance to abacavir was studied with abacavir alone and with abacavir in combination with other nucleoside analogues in cell cultu ...
http://www.aegis.org/aidsline/2000/jun/a0060134.html
File Name: a0060134.html, Size: 10KB, Last Modified: Wednesday, June 28, 2000 at 8:12:04 PM
Abstract: OBJECTIVE: Evaluation of clinical resistance to abacavir in various patient populations and correlation with in vitro phenotypic and genotypic assessments. METHODS: Plasma samples from naive and treatment experienced HIV-1 infected patients adult and pediatric) were assessed for baseline phenotypic and genotypic sensi ...
http://www.aegis.org/aidsline/1998/jun/m9860248.html
File Name: m9860248.html, Size: 10KB, Last Modified: Monday, June 29, 1998 at 6:29:23 AM
Abstract: METHODS: 60 patients with plasma HIV-1 RNA greater than or equal to 30,000 copies/mL (vRNA) and CD4+ counts greater than or equal to 100cells/mm<sup>3</sup>, were randomized to doses of 100, 300 or 600mg BID for 24 weeks. Patients who either completed 24 weeks of abacavir therapy, or met switch criteria base ...
http://www.aegis.org/conferences/croi/1998/658.html
File Name: 658.html, Size: 6KB, Last Modified: Sunday, February 01, 1998 at 8:12:04 PM
Abstract: The drug abacavir can safely increase the potency of combination treatments for HIV positive children who have shown resistance to other therapies, pediatricians say. ...
http://www.aegis.org/pubs/aidswkly/2001/aw010301.html
File Name: aw010301.html, Size: 9KB, Last Modified: Monday, January 05, 2009 at 10:02:10 PM
Abstract: While significantly reconstituting total CD4+, abacavir resulted in significant expansion of activated/senescent/proapoptotic T-cell subsets associated to vascular damage. Analogously to other drug-toxicity models, a specific interference of abacavir with purine signaling pathways might be speculated, leading to impair ...
http://www.aegis.org/conferences/hiv-glasgow/2008/1758-2652-11-s1-p88.html
File Name: 1758-2652-11-s1-p88.html, Size: 12KB, Last Modified: Monday, November 10, 2008 at 7:00:00 AM
Abstract: Because of reported HSR, abacavir has been less attractive in some population, particularly in limited resource country. However, in a Martinican cohort with majority of patients with black African ancestry, abacavir exposure is frequent, HSR rare, and prevalence of HLA B*5701 was low. In Caribbean region, black popula ...
http://www.aegis.org/conferences/iashivpt/2007/mopeb003.html
File Name: mopeb003.html, Size: 9KB, Last Modified: Monday, July 23, 2007 at 6:29:23 AM
Abstract: HLA-B*5701 is more common (13.4%) in our Caucasian Irish patients and HLA-typing has a role in guiding who should be initiated on abacavir treatment with the aim of avoiding adverse drug reactions. Its role in other populations (Black African) is less well defined. ...
http://www.aegis.org/conferences/bhiva/2007/p82.html
File Name: p82.html, Size: 5KB, Last Modified: Thursday, March 29, 2007 at 8:12:04 PM